News | Clinical Decision Support | May 31, 2017

Siemens Healthineers and Fraunhofer MEVIS Announce Research Alliance on Clinical Decision Support

Collaboration will work to develop decision support systems for physicians based on deep machine learning

Siemens Healthineers and Fraunhofer MEVIS Announce Research Alliance on Clinical Decision Support

May 31, 2017 — Siemens Healthineers and the Fraunhofer Institute for Medical Image Computing MEVIS announced the formation of a new research alliance to develop decision support systems for physicians based on deep machine learning. The partners will discuss their joint efforts at the German Radiology Congress, May 24-27 in Leipzig, Germany.

The cooperation contracts for the project, planned to run for four years, were signed recently. Through this collaboration, the partners want to strengthen the bond between their research activities. The aim is not only to develop intelligent decision support systems for clinically relevant problems, but also establish them on the market successfully.

Today, most of the information in clinics and medical practices is stored digitally. Until now image data, findings, lab values, digital patient records and surgery reports are handled separately. However, there is a current trend aimed at gathering this information in one unified software framework. This data integration enables faster handling of medical information and lays the foundation for more efficient interaction between different specialties and to enable more precise and personalized clinical decisions. It also promises added value: New self-learning computer algorithms can detect hidden patterns in the data and give physicians valuable support for their diagnosis and therapy decisions. 

“When it comes to detecting relevant patterns and correlations in complex data volumes, computers are now better than humans,” said Horst Hahn, director of Fraunhofer MEVIS. “This does not mean, however, that computers will make therapy decisions. They will simply support doctors with database-driven knowledge,” he emphasized.

Based on comprehensive databases, the research partners will develop software systems that support clinicians in finding the best possible course of therapy. The work focuses on tumor diseases, such as lung cancer, for which physicians have to determine the necessity of a biopsy, a procedure known to be stressful for patients. The systems of Fraunhofer MEVIS and Siemens Healthineers would support physicians’ decisions in the future. The goal is to let the software display all the information that could be relevant for decision-making. A physician would not have to gather information from separate sources, saving valuable time. Additionally, the guidelines of medical specialist societies will be integrated automatically, providing physicians with valuable support. Ultimately, the algorithms will link the case at hand with a comprehensive database. Which methods have provided the greatest benefit in similar cases? Does a nuclear medicine method such as positron emission tomography (PET)/computed tomography (CT) make more sense than a biopsy?  

Most of all, the new system will help determine the best possible course of therapy. It will enable physicians with different specialties to access one central system to view all relevant information, including e.g. X-ray and magnetic resonance (MR) images, tissue analyses, genetic parameters, lab values and important data from the patient’s medical history. Computer programs will search for patterns in comprehensive databases that could deliver helpful insight into the case at hand: Did surgery outperform radiation therapy in similar cases? Does an ongoing course of chemotherapy bring the anticipated success, or should it be ceased? The partners already have elementary access to necessary reference databases, but much will be developed and completed after the project commences.

For more information: www.mevis.fraunhofer.de

Related Content

The U.S. Food and Drug Administration (#FDA) authorized marketing of #Medtronic's #GIGenius, the first device that uses #artificialintelligence (#AI) based on #machinelearning to assist #clinicians in detecting #lesions (such as #polyps or suspected tumors) in the #colon in real time during a c#olonoscopy.

The GI Genius intelligent endoscopy module works in real-time, automatically identifying and marking (with a green box) abnormalities consistent with colorectal polyps, including small flat polyps.

News | Artificial Intelligence | April 12, 2021
Varian announced it is collaborating with Google Cloud to build an advanced artificial intelligence (AI) based diagnostic platform to aid in the fight against cancer. Varian and Google Cloud AI embarked on a deployment journey, using Neural Architecture Search (NAS) technology via Google Cloud AI Platform, to create AI models for organ segmentation — a crucial and labor-intensive step in radiation oncology that can be a bottleneck in the cancer treatment clinical workflow.
News | Artificial Intelligence | April 08, 2021
April 8, 2021 — Varian announced it is collaborating with Google...
Brain tumors edged out by artificial intelligence: VBrain applies auto-contouring to the three most common types of brain tumors: brain metastasis, meningioma and acoustic neuroma.

Brain tumors edged out by artificial intelligence: VBrain applies auto-contouring to the three most common types of brain tumors: brain metastasis, meningioma and acoustic neuroma.

News | Artificial Intelligence | April 07, 2021
April 7, 2021 — Vysioneer, a leader in a...
Ultrasound is an invaluable diagnostic tool for the early detection of breast cancer, but the classification of lesions is sometimes challenging and time consuming. Could artificial intelligence hold the answer to solving these problems? Graphic courtesy of Chinese Medical Journal

Ultrasound is an invaluable diagnostic tool for the early detection of breast cancer, but the classification of lesions is sometimes challenging and time consuming. Could artificial intelligence hold the answer to solving these problems? Graphic courtesy of Chinese Medical Journal

News | Artificial Intelligence | April 06, 2021
April 6, 2021 — In 2020, the International Agency for Research on...
Nano-X Imaging Ltd (Nanox), an innovative medical imaging technology company, announced that its single-source Nanox.ARC digital x-ray technology has received 510(k) clearance from the US Food and Drug Administration.
News | X-Ray | April 02, 2021
April 2, 2021 — Nano-X Imaging Ltd.